Sulak Patricia J
Department of Obstetrics and Gynecology, Scott & White Clinic/Memorial Hospital and Texas A & M University System Health Science Center, College of Medicine, Temple, TX, USA.
Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):355-74. doi: 10.1016/j.bpobgyn.2007.08.004. Epub 2007 Sep 24.
Oral contraceptives (OCs) remain the most common method of reversible contraception. Despite lowering of oestrogen and progestin content, the same basic design of 21 combination oestrogen plus progestin pills followed by a week of placebo pills has remained. Numerous studies have now documented that the 21/7 regimen needs to be modified. The 7-day hormone-free interval (HFI) in today's low-dose OCs is associated with reduced pituitary-ovarian suppression, allowing for ovarian follicular development, endogenous oestradiol production and possible ovarian cyst formation and ovulation. The 7-day HFI is also associated with hormone withdrawal symptoms that can lead to discontinuation and unintended pregnancy. Modifications in OC regimens are now appearing on the market secondary to the accumulated scientific data on the disadvantages of low-dose 21/7 pills. This article will review the data on problems with standard OC regimens and modifications that can improve the efficacy and side-effect profile.
口服避孕药(OCs)仍然是最常用的可逆性避孕方法。尽管雌激素和孕激素含量有所降低,但21片复方雌激素加孕激素片加一周安慰剂片的基本设计仍未改变。现在大量研究表明,21/7方案需要进行调整。当今低剂量口服避孕药中的7天无激素间隔(HFI)与垂体-卵巢抑制作用减弱有关,这会导致卵巢卵泡发育、内源性雌二醇产生以及可能的卵巢囊肿形成和排卵。7天的无激素间隔还与激素撤退症状有关,这些症状可能导致停药和意外怀孕。由于关于低剂量21/7片缺点的科学数据不断积累,目前市场上出现了口服避孕药方案的调整。本文将综述关于标准口服避孕药方案问题的数据以及可改善疗效和副作用情况的调整方法。